MabCure, Inc. Logo

MabCure, Inc.

MBCI

(1.0)
Stock Price

0,00 USD

-6029.49% ROA

-127.05% ROE

0x PER

Market Cap.

35.100,00 USD

6.74% DER

0% Yield

-2490.3% NPM

MabCure, Inc. Stock Analysis

MabCure, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

MabCure, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (7%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

The stock's ROE indicates a negative return (-127.05%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-6029.49%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

MabCure, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

MabCure, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

MabCure, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

MabCure, Inc. Revenue
Year Revenue Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 2.000.000 100%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

MabCure, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 3.806 100%
2009 402.657 99.05%
2010 352.030 -14.38%
2011 304.200 -15.72%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

MabCure, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 0
2007 0 0%
2008 528.303 100%
2009 730.160 27.65%
2010 667.390 -9.41%
2011 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

MabCure, Inc. EBITDA
Year EBITDA Growth
2006 -4.000
2007 -106.265 96.24%
2008 -526.018 79.8%
2009 -1.314.385 59.98%
2010 -975.869 -34.69%
2011 924.048 205.61%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

MabCure, Inc. Gross Profit
Year Gross Profit Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 2.000.000 100%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

MabCure, Inc. Net Profit
Year Net Profit Growth
2006 -4.000
2007 -106.265 96.24%
2008 -531.478 80.01%
2009 -1.388.637 61.73%
2010 -1.432.654 3.07%
2011 -44.779.672 96.8%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

MabCure, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

MabCure, Inc. Free Cashflow
Year Free Cashflow Growth
2006 -6.000
2007 -90.265 93.35%
2008 -625.301 85.56%
2009 -1.075.436 41.86%
2010 -705.784 -52.37%
2011 145.250 585.91%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

MabCure, Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 -6.000
2007 -90.265 93.35%
2008 -455.081 80.17%
2009 -1.031.001 55.86%
2010 -691.796 -49.03%
2011 145.250 576.28%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

MabCure, Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 0
2007 0 0%
2008 170.220 100%
2009 44.435 -283.08%
2010 13.988 -217.67%
2011 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

MabCure, Inc. Equity
Year Equity Growth
2006 51.000
2007 -49.265 203.52%
2008 19.207.453 100.26%
2009 18.104.598 -6.09%
2010 15.724.959 -15.13%
2011 3.876.037 -305.7%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

MabCure, Inc. Assets
Year Assets Growth
2006 51.000
2007 0 0%
2008 19.493.928 100%
2009 18.937.634 -2.94%
2010 16.207.473 -16.85%
2011 4.811.185 -236.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

MabCure, Inc. Liabilities
Year Liabilities Growth
2006 0
2007 49.265 100%
2008 286.475 82.8%
2009 833.036 65.61%
2010 482.514 -72.64%
2011 935.148 48.4%

MabCure, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0.07x
POCF Ratio
0
PFCF Ratio
-0.56
Price to Book Ratio
0
EV to Sales
0.3
EV Over EBITDA
-0.22
EV to Operating CashFlow
-2.44
EV to FreeCashFlow
-2.39
Earnings Yield
0
FreeCashFlow Yield
-1.78
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0
ROE
-1.27
Return On Assets
-2.59
Return On Capital Employed
-0.18
Net Income per EBT
1.02
EBT Per Ebit
17.28
Ebit per Revenue
-1.42
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.78
Stock Based Compensation to Revenue
0.43
Gross Profit Margin
1
Operating Profit Margin
-1.42
Pretax Profit Margin
-24.53
Net Profit Margin
-24.9

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0.02
Capex to Revenue
-0
Capex to Depreciation
-0.04
Return on Invested Capital
-0.17
Return on Tangible Assets
-60.29
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0.07
Debt to Assets
0.05
Net Debt to EBITDA
-0.17
Current Ratio
0.17
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.07
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.96
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
7.44

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

MabCure, Inc. Dividends
Year Dividends Growth

MabCure, Inc. Profile

About MabCure, Inc.

MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.

CEO
Mr. Jehu Thomas Degerold Hand
Employee
3
Address
21 Sparrow Circle
White Plains, 10605

MabCure, Inc. Executives & BODs

MabCure, Inc. Executives & BODs
# Name Age
1 Mr. Jehu Thomas Degerold Hand
Chief Executive & Financial Officer and Director
70

MabCure, Inc. Competitors